A novel anti-IgE antibody drug ligelizumab allows more than half of patients with chronic spontaneous urticaria to clear symptoms, a phase 2 trial has shown. Published in the NEJM, the 12-week results for the biologic showed that 51% of the patients treated with ligelizumab had complete control of urticaria, as compared with 26% of the ...
New biologic outperforms omalizumab in urticaria
By Michael Woodhead
3 Oct 2019